

Доц. дхн Живко Желев

Списък на публикациите (1990-2017)

Забележка: Списъкът съдържа 107 заглавия, описани в 12 страници.

Импакт-фактор – Journal of Citation Reports (JCR) `2016

- Автореферати – 2
- Монографии – 1
- Глави от книги – 4
- Статии в списания с импакт-фактор – 66
- Статии в реферирани списания без импакт-фактор – 20
- Статии в сборници от конференции – 14

Статиите, отбелязани в червено, са по дисертацията са присъждане на образователната и научна степен „доктор”(2010) – 14

Статиите, отбелязани в синьо, са по дисертацията за присъждане на научната степен „доктор на науките” (2017) – 25

Статии след конкурса за доцент (2011) – 34, от които 16 (10 с импакт-фактор и 6 без импакт-фактор) не са по дисертацията за присъждане на научната степен „доктор на науките”

- Като първи автор – 31
- Като втори автор – 39
- Като трети и следващ автор – 35

- Общ импакт-фактор (по JCR2016) – 435.00
- Индивидуален импакт-фактор – 103.31
- Импакт-фактор на публикациите след конкурса за доцент – 64.07

Автореферати

1. Желев Ж. – Разработване на хибридни нанопробии чрез модифициране на флуоресцентни нанокристали с биоорганични лиганди и прилагането им за биомедицински анализи и фотосенсибилизация, Автореферат за присъждане на образователната и научна степен „доктор”, СНС по Фармация, ВАК, 2010
2. Желев Ж. – Нитроксидните радикали като контрастни субстанции за диагностика на патологии, свързани с нарушения в проницаемостта на кръвоносните съдове и

клетъчния редокс-статус, Автореферат за присъждане на научна степен „доктор на науките”, Тракийски университет, Стара Загора, 2017

Монографии

1. Желев Ж., Р. Бакалова. – Нанотехнологии за биомедицинска диагностика. Част I. Квантови точки, Университетско издателство „Св. Климент Охридски”, София, България, 2011, 84 стр., ISBN: 978-954-07-3193-3

Глави от книги

2. Kagan V., L. Packer, E. Serbinova, R. Bakalova, D. Stoyanovsky, Z. Zhelev, M. Harfouf, S. Kitanova, and D. Rangelova. – Mechanisms of vitamin E control of lipid peroxidation: regeneration, synergism, asymmetry, migration, and metal chelation, “Biological Oxidation Systems” (ed. C. Reddy), Academic Press, New York, 1990, p. 5-13 (статията включва оригинални резултати).
3. Kagan V., R. Bakalova, Z. Zhelev, E. Serbinova, S. Ribarov, and L. Packer. – Intermembrane transfer of alpha-tocopherol and its homologues, “Vitamin E: Biochemistry and Health Implications” (eds. Packer L., and J. Fuchs), Marcel Dekker, New York, 1992, p. 171-178 (статията включва оригинални резултати).
4. Kubo T., R. Bakalova, Z. Zhelev, H. Ohba, and M. Fujii. – Controlled intracellular localization of oligonucleotides by chemical conjugation, “Non-viral Gene Therapy: Gene Design and Delivery” (eds. Taira K., K. Kataoka, and T. Niidome), Springer-Verlag, Tokyo, 2005, p. 187-197 (статията включва оригинални резултати).
5. **Bakalova R., Z. Zhelev, H. Ohba, and Y. Baba. – Quantum dot-based nanobiohybrids for fluorescent detection of molecular and cellular biological targets, “Nanotechnologies for Life Science” (ed. Chala Kumar), Wiley-VCH Verlag GmbH, Weinheim, Germany, 2007, Vol. 8, p. 175-207 (статията включва оригинални резултати).**

Оригинални статии (в пълен текст)

6. Kagan V., R. Bakalova, Z. Zhelev, D. Rangelova, E. Serbinova, V. Tyurin, N. Denisova, and L. Packer. – Intermembrane transfer and antioxidant action of alpha-tocopherol in liposomes, Arch. Biochem. Biophys., **280**(1), 1990, 147-152, impact factor – 3.165.
7. Rangelova D., Z. Zhelev, R. Bakalova, V. Tyurin, N. Denisova, E. Serbinova, L. Peker, and V. Kagan. – Intermembrane transfer and antioxidant action of alpha-tocopherol in liposomes, Bull. Exp. Biol. Med., **109**(1), 1990, 37-39 [на руски и английски език], impact factor – 0.456.

8. Bakalova R., A. Goudev, Z. Zhelev, and Ch. Nachev. – Oxidative modifications of blood serum in humans with coronary artery disease, *Acta Phys. Pharmacol. Bulg.*, **21**(3-4), 1995, 81-85.
9. Bakalova R., A. Goudev, and Z. Zhelev. – Computer correlative analysis and mathematical moulding of antioxidant status and level of lipid peroxidation in blood plasma and plasma lipoproteins in atherogenesis, “Proceedings of the First Bulgarian International Symposium on Cardiovascular Diseases and Pediatric Traumatology”, Medical Service Corporation International, Arlington, USA, 1995, Vol. I, p. 10-17.
10. Bakalova R., A. Goudev, Z. Zhelev, Ch. Nachev, and St. Ribarov. – Oxidative modification of low density lipoproteins leads to disturbance of their binding with alpha-tocopherol, *Gen. Physiol. Biophys.*, **15**(6), 1996, 463-475, impact factor – 1.170.
11. Bakalova R., Z. Zhelev, A. Goudev, St. Ribarov, and Ch. Nachev. – Serum levels of IgG autoantibodies against oxidized low density lipoproteins and lag-phase of serum oxidation in patients with coronary heart disease – an inverse correlation, *Gen. Physiol. Biophys.*, **18**(1), 1999, 87-97, impact factor – 1.170.
12. Zhelev Z., and R. Bakalova. – Laser-Doppler imaging of activation-flow coupling in the somatosensory cortex: Normalization of signal when the baseline changes significantly, *Meth. Find. Exp. Clin. Pharmacol.*, **24**(9), 2002, 1-6, impact factor (JCR2010) – 0.774.
13. Ohba H., Z. Zhelev, R. Bakalova, A. Ewis, T. Omori, M. Ishikawa, Y. Shinohara, and Y. Baba. – Inhibition of bcr-abl and/or c-abl gene expression by small interfering double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes, *Cancer*, **101**(6), 2004, 1390-1403, impact factor – 5.997.
14. Zhelev Z., R. Bakalova, H. Ohba, A. Ewis, M. Ishikawa, Y. Shinohara, and Y. Baba. – The suppression of bcr-abl synthesis by siRNAs and protein tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic and cell proliferation factors (microarray study), *FEBS Lett.*, **570**(1-3), 2004, 195-204, impact factor – 3.623.
15. Bakalova R., H. Ohba, Z. Zhelev, T. Kubo, M. Fujii, M. Ishikawa, Y. Shinohara, and Y. Baba. – Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells, *FEBS Lett.*, **564**(1-2), 2004, 73-84, impact factor – 3.623.
16. Zhelev Z., H. Ohba, R. Bakalova, V. Hadjimitova, M. Ishikawa, Y. Shinohara, and Y. Baba. – Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes, *Cancer Chemother. Pharmacol.*, **53**(3), 2004, 267-275, impact factor – 2.737.
17. Bakalova R., H. Ohba, Z. Zhelev, T. Kubo, M. Fujii, M. Ishikawa, Y. Shinohara, and Y. Baba. – Protein-kinase C-zeta, but not conventional Ca²⁺-dependent protein-kinase C

isoenzymes nor Ca^{2+} -calmodulin, participates in regulation of telomerase activity in Burkitt's lymphoma cells, *Cancer Chemother. Pharmacol.*, **54**(2), 2004, 161-172, impact factor – 2.737.

18. Bakalova R., H. Ohba, Z. Zhelev, T. Nagase, R. Jose, M. Ishikawa, and Y. Baba. – Quantum dot anti-CD conjugates: Are they potential photosensitizers or potentiators of classical photosensitizing agents in photodynamic therapy of cancer? *Nano Lett.*, **4**(9), 2004, 1567-1573, impact factor – 12.712.
19. Zhelev Z., R. Jose, T. Nagase, H. Ohba, R. Bakalova, M. Ishikawa, and Y. Baba. – Enhancement of the photoluminescence of CdSe quantum dots during long-term UV-irradiation: privilege or fault in life science research? *J. Photochem. Photobiol. B*, **75**(1-2), 2004, 99-105, impact factor – 2.673.
20. Bakalova R., Z. Zhelev, H. Ohba, M. Ishikawa, and Y. Baba. – Quantum dots as photosensitizers? *Nature Biotechnology*, **22**(11), 2004, 1360-1361, impact factor – 41.667.
21. Bakalova R., Z. Zhelev, R. Jose, H. Ohba, T. Nagase, S. Fukuoka, M. Ishikawa, Y. Shinohara, and Y. Baba. – Microscopic imaging and identification of leukemic cells from normal lymphocytes using quantum dot-lectin conjugates, “Proceedings of the 8th Asia Pacific Conference on Electron Microscopy”, Kanazawa, Japan, June 7-11, 2004, p. 372-373.
22. Zhelev Z., H. Ohba, R. Bakalova, R. Jose, T. Nagase, M. Ishikawa, and Y. Baba. – Quantum dot-lectin conjugates as new fluorescent markers for microscopic and flow cytometric identification of leukemia cells from normal lymphocytes, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 36-37.
23. Zhelev Z., R. Bakalova, R. Jose, H. Ohba, M. Ishikawa, and Y. Baba. – Highly luminescent quantum dot bioconjugates for ultrasensitive detection of “tracer” proteins by flow cytometry and immunoblot, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 38-39.
24. Bakalova R., Z. Zhelev, A. Ewis, H. Ohba, M. Ishikawa, Y. Shinohara, and Y. Baba. – Microarray-based technology for discovery of multi-drug resistance factors in gene therapy of cancer, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 24-25.
25. Nagase T., T. Shibata, Z. Zhelev, R. Jose, R. Bakalova, V. Biju, Y. Makita, Y. Shinohara, M. Ishikawa, and Y. Baba. – Synthesis of luminescent CdSe/ZnS core-shell nanocrystals

- via @green@ chemical approach using zinc acetate as a zinc precursor, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 46-47.
26. Jose R., Z. Zhelev, T. Nagase, Y. Shinohara, Y. Baba, and M. Ishikawa. – Room-temperature passivation of CdX (X = Se, Te) quantum dots with homoepitaxial layers for enhanced luminescence efficiency, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 62-63.
 27. Jose R., Z. Zhelev, T. Nagase, Y. Mkiti, R. Bakalova, H. Ohba, Y. Shinohara, Y. Baba, and M. Ishikawa. – Synthesis of highly luminescent CdSe quantum dots at room temperature, “Proceedings of the Third International Symposium on Single-Molecule Bioanalysis and Nano-biodevice (SMBN2004)”, Takamatsu, Japan, November 24-25, 2004, Vol. II, p. 64-65.
 28. Jose R., Z. Zhelev, T. Nagase, Y. Shinohara, Y. Baba, and M. Ishikawa. – Dependence of photoluminescence efficiency of CdSe quantum dots on chemical environments: Effect of acetate ions and other organic solvents, Proceedings of the Annual Meeting of AIST-Japan, February 4, 2004, p. 1-3.
 29. Zhelev Z., A. Ewis, R. Bakalova, F. Dang, H. Ohba, M. Ishikawa, Y. Shinohara, and Y. Baba. – Possibility for quantification of non-radioactive telomerase activity assay by microchip electrophoresis, “Proceedings of the Fourth International Symposium on Microchemistry and Microsystems (ISMM2004)”, Takamatsu, Japan, November 24-26, 2004, Vol. II, p. 74-75.
 30. Kubo T., Z. Zhelev, H. Ohba, M. Fujii, M. Mileva, R. Bakalova, M. Ishikawa, and Y. Baba. – A new procedure for solid-phase synthesis of oligo-DNA-peptide conjugates and verification of their biological properties, “Proceedings of the Fourth International Symposium on Microchemistry and Microsystems (ISMM2004)”, Takamatsu, Japan, November 24-26, 2004, Vol. II, p. 56-57.
 31. Bakalova R., Z. Zhelev, H. Ohba, and Y. Baba. – Quantum dot-conjugated hybridization probes for preliminary screening of siRNA sequences, *J. Am. Chem. Soc.*, **127**(32), 2005, 11328-11335, impact factor – 13.858.
 32. Bakalova R., Z. Zhelev, H. Ohba, and Y. Baba. – Quantum dot-based western blotting technology for ultrasensitive detection of “tracer” proteins, *J. Am. Chem. Soc.*, **127**(25), 2005, 9328-9329, impact factor – 13.858.
 33. Zhelev Z., H. Ohba, R. Bakalova, R. Jose, S. Fukuoka, T. Nagase, M. Ishikawa, and Y. Baba. – Fabrication of quantum dot-lectin conjugates as novel fluorescent probes for microscopic and flow cytometric identification of leukemia cells from normal

- lymphocytes, *Chemical Communications (Camb.)*, (15), 2005, 1980-1982, impact factor – 6.319.
34. Bakalova R., Z. Zhelev, R. Jose, T. Nagase, H. Ohba, M. Ishikawa, and Y. Baba. – Role of free Cd and Se ions in the potential mechanism for the enhancement of photoluminescence of CdSe quantum dots under UV-irradiation, *J. Nanosci. Nanotechnol.*, **5**(6), 2005, 887-894, impact factor – 1.483.
35. Zhelev Z., R. Bakalova, A. Ewis, H. Ohba, M. Ishikawa, and Y. Baba. – Non-radioactive telomerase activity assay by microchip electrophoresis – privileges to the classical gel electrophoresis assay, *Electrophoresis*, **26**(15), 2005, 3021-3024, impact factor – 2.744.
36. Kubo T., Z. Zhelev, R. Bakalova, H. Ohba, and M. Fujii. – Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation, *Org. Biomol. Chem.*, **3**(18), 2005, 3257-3259, impact factor – 3.564.
37. Kubo T., R. Bakalova, Z. Zhelev, H. Ohba, and M. Fujii. – Synthesis, biological properties and antisense effects of oligonucleotide-peptide conjugates, *Frontiers in Organic Chemistry*, **1**, 2005, 229-241.
38. Bakalova R., T. Kubo, M. Mileva, Z. Zhelev, H. Ohba, and M. Fujii. – A potential of DNA-sugar conjugates as antisense-based drugs, *Pharmacy*, **52**(1-2), 2005, 3-6.
39. Kubo T., R. Bakalova, Z. Zhelev, H. Ohba, and M. Fujii. – Highly sensitive inhibition of hTERT mRNA expression and telomerase activity by DNA-signal-peptide conjugates, *Nucleic Acids Res. Ser. (Oxf.)*, (49), 2005, 337-338.
40. Takamori K., T. Kubo, Z. Zhelev, R. Bakalova, H. Ohba, K. Doi, and M. Fujii. – Suppression of bcr/abl chimeric gene by conjugate DNA enzymes in human cells, *Nucleic Acids Symp. Ser. (Oxf.)*, (49), 2005, 333-334.
41. Bakalova R., Z. Zhelev, I. Aoki, H. Ohba, Y. Imai, and I. Kanno. – Silica-shelled single quantum dot micelles as novel imaging probes with dual or multimodality, *Anal. Chem.*, **78**(16), 2006, 5925-5932, impact factor – 6.320.
42. Zhelev Z., H. Ohba, and R. Bakalova. – Silica-shelled single quantum dot micelles as potentially non-cytotoxic fluorescent cell tracers, *J. Am. Chem. Soc.*, **128**(19), 2006, 6324-6325, impact factor – 13.858.
43. Zhelev Z., R. Bakalova, H. Ohba, R. Jose, Y. Imai, and Y. Baba. – Uncoated, broad fluorescent and size-homogenous CdSe quantum dots for ultrasensitive bioanalyses, *Anal. Chem.*, **78**(1), 2006, 321-330, impact factor – 6.320.
44. Jose R., Z. Zhelev, T. Nagase, R. Bakalova, Y. Baba, and M. Ishikawa. – Self-surface passivation of CdX (X= Se, Te) quantum dots at room temperature, *J. Nanosci. Nanotechnol.*, **6**(3), 2006, 618-623, impact factor – 1.483.

45. Jose R., Z. Zhelev, R. Bakalova, Y. Baba, and M. Ishikawa. – White-light emitting quantum dots synthesized at room temperature, *Appl. Phys. Lett.*, **89**, 2006, 013115-013117, impact factor – 3.411.
46. Zhelev Z., R. Jose, R. Bakalova, Y. Imai, T. Kubo, H. Ohba, and H. Noma. – Photoluminescent properties of CdSe quantum dots at different synthetic conditions – relationship with structure and surface ligands, *Transactions of Materials Research Society of Japan*, **31(2)**, 2006, 441-444.
47. Zhelev Z., R. Bakalova, and H. Ohba. – A composition of fluorescent nanoparticles and their application in life science, “Proceedings of 44th Symposium on Powder Science and Technology”, Kitakyushu, Japan, September 20-22, 2006, p. 1-5.
48. Bakalova R., Z. Zhelev, I. Aoki, and I. Kanno. – Designing quantum dot probes, *Nature Photonics*, **1(9)**, 2007, 487-489, impact factor – 37.852.
49. Zlateva G., Z. Zhelev, R. Bakalova, and I. Kanno. – Precize size control and synchronized synthesis of six colors of CdSe quantum dots in a slow-increasing temperature gradient, *Inorganic Chemistry*, **46(16)**, 2007, 6212-6214, impact factor – 4.857.
50. Kubo T., Z. Zhelev, H. Ohba, and R. Bakalova. – Modified 27nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity, *Oligonucleotides (Nucleic Acid Therapeutics)*, **17**, 2007, 1-20, impact factor – 2.338.
- (в тази статия участието на T. Kubo и Z. Zhelev трябва да се счита за еквивалентно)
51. Bakalova R., Z. Zhelev, T. Kubo, M. Mileva, and H. Ohba. – Dual-labeled telomere sensing probes for quantification of telomerase activity assay, *J. Biochem. Biophys. Meth. (J. Proteomics)*, **70(3)**, 2007, 503-506, impact factor – 3.914.
52. Kubo T., Z. Zhelev, R. Bakalova, and H. Ohba. – Enhancement of gene silencing potency and nuclease stability by chemically modified duplex RNA, *Nucl. Acids Symp. Ser. (Oxf.)*, (51), 2007, 407-408.
53. Kubo T., Z. Zhelev, H. Ohba, and R. Bakalova. – Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect, *Biochem. Biophys. Res. Commun.*, **365**, 2008, 54-61, impact factor – 2.466.
54. Bakalova R., Z. Zhelev, I. Aoki, K. Masamoto, M. Mileva, T. Obata, M. Higuchi, V. Gadjeva, and I. Kanno. – Multimodal silica-shelled quantum dots: Direct intracellular delivery, photosensitization, toxic and microcirculation effects, *Bioconjugate Chemistry*, **19(6)**, 2008, 1135-1142, impact factor – 4.818.
55. Kubo T., Z. Zhelev, R. Bakalova, and H. Ohba. – Highly efficient gene suppression by chemically modified 27 nucleotide double-stranded RNAs, *Jpn. J. Appl. Phys.*, **47(2)**,

2008, 1346-1350, impact factor – 1.384.

56. Bakalova R., I. Aoki, Z. Zhelev, and I. Kanno. – Quantum dots: from multimodal imaging diagnostics to radiation-induced photodynamic therapy of cancer, “Proceedings of the Second Symposium of Molecular Imaging Center”, NIRS-Chiba, October 19, 2007, Chiba, Japan, Ed. by National Institute of Radiological Sciences, Chiba, Japan, 2008, p. 32-38 [in English/Japanese].
57. Zhelev Z., K. Matsumoto, R. Bakalova, V. Gadjeva, A. Zheleva, I. Aoki, K. Anzai, and I. Kanno. – EPR signal reduction kinetic of nitroxyl-labeled anticancer drugs in blood in vitro and in vivo, *Gen. Physiol. Biophys.*, **28**(4), 2009, 356-362, impact factor – 1.170.
58. Zhelev Z., R. Bakalova, I. Aoki, K. Matsumoto, V. Gadjeva, K. Anzai, and I. Kanno. – Nitroxyl radicals as low toxic spin-labels for non-invasive magnetic resonance imaging of blood-brain barrier permeability for conventional therapeutics, *Chemical Communications (Cambridge)*, (1), 2009, 53-55, impact factor – 6.319.
59. Zhelev Z., R. Bakalova, I. Aoki, K. Matsumoto, V. Gadjeva, K. Anzai, and I. Kanno. – Nitroxyl radicals as for spin-labeling of conventional therapeutics and non-invasive magnetic resonance imaging of their permeability for blood-brain barrier: Relationship between structure, blood clearance and MRI signal dynamic in the brain, *Molecular Pharmaceutics*, **6**(2), 2009, 504-512, impact factor – 4.444.
60. Zhelev Z., R. Bakalova, I. Aoki, V. Gadjeva, and I. Kanno. – Imaging of cancer by redox mediated mechanism’ a radical diagnostic approach, *Molecular BioSystems*, **6**(12), 2010, 2386-2388, impact factor – 2.781.
61. Zhelev Z., R. Bakalova, S. Shibata, V. Gadjeva, L. Spasov, and I. Aoki. – Magnetic resonance imaging of brain neuroblastoma based on nitroxide redox cycle, *Trakia J. Sci*, **8**, 2010, 1-5.
62. Bakalova R., Z. Zhelev, D. Kokuryo, L. Spasov, I. Aoki, and T. Saga. – Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics, *Int. J. Nanomedicine*, 2011, **6**, 1719-1732, impact factor – 4.300.
63. Tomizawa A., I. Ishii, Z. Zhelev, I. Aoki, S. Shibata, M. Kitada, and R. Bakalova. – Carbamoyl-PROXYL-enhanced MRI detects very small disruptions in brain vascular permeability induced by dietary cholesterol, *Biochim. Biophys. Acta*, 2011, **1810**(12), 1309-1316, impact factor – 4.702.
64. Tomizawa A., G. Hadjidekov, I. Ishii, R. Bakalova, Z. Zhelev, I. Aoki, T. Saga, and I. Kitada. – Nitroxide derivatives for imaging of hypercholesterolemia-induced kidney dysfunction and assessing the effectiveness of antilipidemic drugs, *Molecular Pharmaceutics*, 2011, **8**(5), 1962-1969, impact factor – 4.444.

След конкурса за „доцент”

65. Bakalova R., G. Hadjidekov, Z. Zhelev, G. Zlateva, L. Spasov, and I. Aoki. – Experimental model for evaluation of renal function using prototype of contrast substance and MRI, *Roentgenology & Radiology (Bulgaria)*, 2011, **XLX(4)**, 197-201.
66. Zhelev Z., V. Gadjeva, I. Aoki, R. Bakalova, and T. Saga. – Cell-penetrating nitroxides as molecular sensors for imaging of cancer in vivo, based on tissue redox activity, *Mol. BioSystems*, 2012, **8(10)**, 2733-2740, impact factor – 2.781.
67. Nikolova B., A. Kostadinova, B. Dimitrov, Z. Zhelev, R. Bakalova, I. Aoki, T. Saga, and I. Tsoneva. – Fluorescent imaging for assessment of the effect of combined application of electroporation and rifampicin on HaCaT cells as a new therapeutic approach for psoriasis, *Sensors (Basel)*, 2013, **13(3)**, 3625-3634, impact factor – 2.677.
68. Zhelev Z., I. Aoki, V. Gadjeva, B. Nikolova, R. Bakalova, and S. Saga. – Tissue redox activity as a sensing platform for imaging of cancer based on nitroxide redox cycle, *Eur. J. Cancer*, 2013, **49(6)**, 1467-1478, impact factor – 6.029.
69. Bakalova R., Z. Zhelev, I. Aoki, and T. Saga. – Tissue redox activity as a hallmark of carcinogenesis: from early to terminal stages of cancer, *Clinical Cancer Research*, 2013, **19(9)**, 2503-2517, impact factor – 9.619.
70. Zhelev Z., R. Bakalova, I. Aoki, D. Lazarova, and T. Saga. – Imaging of superoxide generation in the dopaminergic area of the brain in Parkinson's disease, using mito-TEMPO, *ACS Chem. Neurosci.*, 2013, **4(11)**, 1439-1445, impact-factor – 3.883.
71. Atanasova S., D. Lazarova, B. Nikolova, Z. Zhelev, T. Tsoneva, I. Aoki, and R. Bakalova. – In vivo visualization of electro-assisted delivery of nanoparticles in cancer using optical imaging, *Anticancer Res. (Suppl)*, 2014, **34**, 5819-5821.
72. Georgieva E., D. Ivanova, D. Lazarova, R. Bakalova, I. Aoki, and Z. Zhelev. – In vitro analysis of redox status of normal and tumor cells using nitroxide radicals and EPR spectroscopy, *Anticancer Res. (Suppl.)*, 2014, **34**, 5917-5919.
73. Ivanova D., D. Lazarova, E. Georgieva, I. Aoki, Z. Zhelev, and R. Bakalova. – Systematic study on the cytotoxic and/or cytostatic effects of over twenty anticancer drugs: The crucial importance of the analytical approach and data processing, *Anticancer Res. (Suppl.)*, 2014, **34**, 5825-5827.
74. Zhelev Z., D. Ivanova, I. Aoki, T. Saga, and R. Bakalova. – 2-Deoxy-D-glucose sensitizes cancer cells to Barasertib and Everolimus by ROS-independent mechanism(s), *Anticancer Res.*, 2015, **35(12)**, 6623-6632, impact factor – 1.937.

75. Bakalova R., E. Georgieva, D. Ivanova, Z. Zhelev, I. Aoki, and T. Saga. – Magnetic resonance imaging of mitochondrial dysfunction and metabolic activity, accompanied by overproduction of superoxide, *ACS Chem. Neurosci.*, 2015, **6**(12), 1922-1929, impact factor – 3.883.
76. Bakalova R., Z. Zhelev, B. Nikolova, S. Murayama, I. Tsoneva, I. Aoki, and T. Saga. – Lymph node mapping using quantum dot-labeled polymersomes. *Gen. Physiol. Biophys.*, 2015, **34**(4), 393-398, impact factor – 1.170.
77. Bakalova R., D. Lazarova, B. Nikolova, S. Atanasova, G. Zlateva, Z. Zhelev, and I. Aoki. – Delivery of size-controlled long-circulating polymersomes in solid tumors, visualized by quantum dots and optical imaging in vivo, *Biotechnol. Biotechnol. Equip.*, 2015, **29**, 175-180, impact factor – 1.059.
78. Nikolova B., S. Atanasova, T. Mudrov, I. Tsoneva, Z. Zhelev, R. Bakalova, and I. Aoki. – Image-guided electro-assisted drug delivery: Comparison between two types of electrodes. *Int. J. Bioautomation*, 2015, **19**(2), 259-266 [in English].
79. Atanasova S., B. Nikolova, I. Tsoneva, S. Murayama, I. Aoki, Z. Zhelev, and R. Bakalova. – Visualization of delivery and localization of fluorescent nanoparticles in tumors after electroporation: experimental models in vivo. In: *Proceedings of the International Symposium “Light in Medicine”*, June 3-4, 2015, Sofia, Bulgaria [in Bulgarian – on line].
80. Bakalova R., B. Nikolova, S. Murayama, S. Atanasova, Z. Zhelev, I. Aoki, M. Kato, I. Tsoneva, and T. Saga. – Passive and electro-assisted delivery of hydrogel nanoparticles in solid tumors, visualized by optical and magnetic resonance imaging, *Anal. Bioanal. Chem.*, 2016, **408**(3), 905-914, impact factor – 3.431.
81. Atanasova S., B. Nikolova, S. Murayama, E. Stoyanova, I. Tsoneva, Z. Zhelev, I. Aoki, and R. Bakalova. – Electroinduced delivery of hydrogel nanoparticles in Colon 26 cells, visualized by confocal fluorescent system, *Anticancer Res.*, 2016, **36**(9), 4601-4606, impact factor – 1.937.
82. Georgieva E., Z. Zhelev, I. Aoki, R. Bakalova, and T. Higashi. – Detection of redox imbalance in normal lymphocytes with induced mitochondrial dysfunction – EPR study, *Anticancer Res.*, 2016, **36**(10), 5273-5279, impact factor – 1.937.
83. Zhelev Z., D. Ivanova, R. Bakalova, I. Aoki, and T. Saga. – Inhibition of pentose-phosphate pathway through 6-aminonicotinamide sensitizes leukemia lymphocytes, but not normal lymphocytes, to chemotherapeutics by ROS-independent mechanism, *Anticancer Res.*, 2016, **36**(11), 6011-6020, impact factor – 1.937.
84. Zhelev Z., D. Ivanova, D. Lazarova, I. Aoki, R. Bakalova, and T. Saga. –

Docosahexaenoic acid sensitizes leukemia lymphocytes to barasertib and everolimus by ROS-dependent mechanism without affecting the level of ROS and viability of normal lymphocytes, *Anticancer Res.*, 2016, **36**(4), 1673-1682, impact factor – 1.937.

85. Zhelev Z., D. Ivanova, R. Bakalova, I. Aoki, and T. Higashi. – Synergistic cytotoxicity of melatonin and new-generation anticancer drugs against leukemia lymphocytes, but not normal lymphocytes, *Anticancer Res.*, 2017, **37**(1), 149-159, impact factor – 1.937.
86. Bakalova R., D. Lazarova, G. Zlateva, Z. Zhelev, L. Spassov, and I. Aoki. – Visualization of overproduction of superoxide in living cells using nitroxide-enhanced MRI – new insights on the molecular nature of functional MRI, In: “Annals of Sofia University “St. Kliment Ohridski”, Faculty of medicine, St. Kliment Ohridski University Press, Sofia, Bulgaria, 2017, Vol. 2, pp. 123-134.
87. Bakalova R., Z. Zhelev, S. Shibata, B. Nikolova, I. Aoki, and T. Higashi. – Impressive suppression of colon cancer growth by triple combination SN38/EF24/melatonin: “Oncogenic” versus “onco-suppressive” reactive oxygen species, *Anticancer Res.*, 2017, **37**(10), 5449-5458, impact factor – 1.937.
88. Semkova S., B. Nikolova, Z. Zhelev, I. Tsoneva, G. Zlateva, I. Aoki, and R. Bakalova. – Loading efficiency of polymersomes with contrast agents and their intracellular delivery: Quantum dots versus organic dyes. *Anticancer Res.*, 2018, **38** [in Press], impact factor – 1.937.
89. Ivanova D., Z. Zhelev, D. Lazarova, P. Getsov, R. Bakalova, and I. Aoki. – Vitamins C and K3: A powerful redox system for sensitizing leukemia lymphocytes to everolimus and barasertib. *Anticancer Res.*, 2018, **38** [in Press], impact factor – 1.937.

Обзорни статии

90. Zhelev Z., and R. Bakalova. – Effect of vitamins E and C on transplant-associated atherosclerosis, *Lancet*, **360**(9331), 2002, 487, impact factor – 47.831.
91. Bakalova R., Z. Zhelev, and H. Ohba. – Decrease of resistance to imatinib in leukaemia, *Lancet*, **359**(9319), 2002, 1776-1777, impact factor – 47.831.
92. Bakalova R., H. Ohba, Z. Zhelev, M. Ishikawa, Y. Shinohara, and Y. Baba. – Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase - a potential reason for resistance to Gleevec in chronic myelogenous leukemia, *Biochemical Pharmacol.*, **66**(10), 2003, 1879-1884, impact factor – 4.581.
93. Ewis A., Z. Zhelev, R. Bakalova, S. Fukuoka, Y. Shinohara, M. Ishikawa, and Y. Baba. – A history of microarray in biomedicine, *Expert Review of Molecular Diagnosis*, **5**(3),

2005, 315-328, impact factor – 3.100.

94. Ohba H., Z. Zhelev, and R. Bakalova. – Application of quantum dots for bioimaging, *Nippon Rinsho (Cell Technology)*, **25(8)**, 2006, 894-897 [на японски език] (статията съдържа оригинални резултати).
95. Bakalova R., Z. Zhelev, and H. Ohba. – Quantum dots open new trends in biosensor evolution, *Sensor Lett.*, (4), 2006, 1-3, impact factor (JCR2013) – 0.558.
96. Bakalova R., Z. Zhelev, and V. Gadjeva. – Quantum dots versus organic fluorophores in fluorescent deep-tissue imaging – merits and demerits, *Gen. Physiol. Biophys.*, **27(4)**, 2008, 231-242, impact factor – 1.170.

След конкурса за „доцент”

97. Zhelev Z., G. Hadjidekov, G. Zlateva, D. Lazarova, L. Spasov, and R. Bakalova. – Problems of fluorescent imaging diagnostic and their solution using nanofluorophores. Part II: Multifunctional and multimodal nanoparticles and their application for bioimaging, *Roentgenology & Radiology (Bulgaria)*, 2011, **XLX(4)**, 258-270.
98. Bakalova R., Z. Zhelev, and L. Spasov. – Nilotinib vs Imatinib – molecular mechanisms of its better efficiency, *Cancer*, 2012, **118(20)**, 5180-5181, impact factor – 5.997.
99. Zhelev Z., G. Hadjidekov, G. Zlateva, L. Spasov, and R. Bakalova. – Problems of fluorescent imaging diagnostic and their solution using nanofluorophores. Part I: Advantages of fluorescent nanoparticles over conventional organic fluorophores, *Roentgenology & Radiology (Bulgaria)*, 2012, **LI(1)**, 6-17.
100. Ivanova D., R. Bakalova, V. Gadjeva, Lazarova D., and Z. Zhelev. – The impact of reactive oxygen species in anticancer therapeutic strategies, *Adv. Clin. Exp. Med.*, 2013, **22(6)**, 899-908, impact-factor – 1.179.
101. Ivanova D., E. Georgieva, D. Lazarova, V. Gadjeva, R. Bakalova, and Z. Zhelev. – Redox-modulating and/or antioxidant properties of nitroxides – a potential reason for decreasing side-effects of cancer therapy, *Trakia J. Sci.*, 2014, (3), 329-337.
102. Ivanova D., Z. Zhelev, I. Aoki, R. Bakalova, and T. Higashi. – Overproduction of reactive oxygen species – obligatory or not for induction of apoptosis by anticancer drugs? *Chin. J. Cancer Res.*, 2016, **28(4)**, 383-396, impact factor – 3.000.
103. Zhelev Z. – Nitroxide radicals as contrast substances for magnetic resonance imaging diagnostics: Part 1. *Roentgenology & Radiology (Bulgaria)*, 2016, **LV(4)**, 236-253.
104. Zhelev Z. – Nitroxide radicals as contrast substances for magnetic resonance imaging of pathologies, associated with abnormalities in cellular redox-status and induction of oxidative stress: Part 2. *Roentgenology & Radiology (Bulgaria)*, 2017, **LVI(1)**, 13-26.

105. Georgieva E., D. Ivanova, Z. Zhelev, R. Bakalova, M. Gulubova, and I. Aoki. – Mitochondrial dysfunction and redox imbalance as a diagnostic marker of “free radical diseases”, *Anticancer Res.*, 2017, **37**(10), 5373-5381, impact factor – 1.937.

Ж. Желев

Списък на публикациите
януари, 2018